The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Understanding and overcoming resistance to BTK and BCL-2 inhibitors in CLL
Thomas Kipps, MD, PhD, UC San Diego, Moores Cancer Center, La Jolla, CA, comments on the importance of evaluating the types of mutations causing resistance to either BTK inhibitors or BCL-2 inhibitors in patients with chronic lymphocytic leukemia (CLL). Dr Kipps explains the most common mechanism of resistance to ibrutinib, highlighting the possibility of using non-covalent BTK inhibitors or BTK degraders in this setting. In addition, Dr Kipps notes the importance of inhibiting other survival pathways for leukemia cells to prevent patients from developing resistance to these agents in the first place. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
